3B Blackbio DX Ltd
3B Blackbio DX Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #33 of 33 in Healthcare Services
See the sector's top 10 — free with your mobile number.
3B Blackbio DX Ltd Q1 FY26 key numbers
- Revenue
- TRUPCR UK export revenue expected to grow by at least 30% this year, reaching INR 17-18 crores.
As stated in 3B Blackbio DX Ltd's Q1 FY26 earnings call transcript · published 1 Jun 2026. Reported figures, not investment advice.
The short version
Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years (Page 20). Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years; export growth targeted at 20% to 25% CAGR.
From 3B Blackbio DX Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years (Page 20).
- Export business projected to grow at 20% to 25% CAGR, with potential for higher growth due to tender orders (Page 19-20).
- TRUPCR UK export revenue expected to grow by at least 30% this year, reaching INR 17-18 crores (Page 12).
- Coris acquisition sales to grow from €5.2 million, driven by AMR products and R&D pipeline, with a conservative PCR sales estimate of €0.7-1 million over 2-3 years (Page 11-15).
- Overall molecular diagnostics segment targeting combined growth of 15% to 20% (Page 9, 20).
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Molecular diagnostics business is not capital intensive; clean rooms and equipment needed are currently utilized at about 65% capacity.
- For next 2 years, only minor capital investment expected, around INR 1 to 2 crores, mainly for facility upgrades or specific equipment for R&D.
- No plans to buy very expensive equipment like MGS technology requiring INR 7 crores investment; alternate approaches are being used.
- Coris acquisition is already integrated financially, with no major additional cash infusion needed for next 1-2 years due to adequate cash position.
2 more points from 3B Blackbio DX Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- It is mentioned that sometimes big tender orders come unexpectedly, which cannot be projected immediately.
- The company maintains a conservative growth estimate (e.g., 20%-25% growth in exports) partly to manage the uncertainty of large orders.
- For the Coris acquisition, no immediate cash infusion for working capital or capacity is expected as they have sufficient cash and low debt.
- The company actively pursues new acquisitions globally to synergize and grow, indicating potential future orders linked to these efforts.
3B Blackbio DX Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Aster DM Quality Care Ltd (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
- Dr Agarwals Health Care Ltd (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
- Syngene Intl. (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
- Yatharth Hospital & Trauma Care Services Ltd (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q1 FY26 results?
Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years (Page 20). Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years; export growth targeted at 20% to 25% CAGR.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 17.7 with a market cap of ₹1,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
Molecular diagnostics business is not capital intensive; clean rooms and equipment needed are currently utilized at about 65% capacity.
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.